A 48-year-old man with chronic myeloid leukemia (CML) in chronic phase is started on imatinib mesylate. At 3 months, BCR-ABL transcript levels are detectable by quantitative PCR despite compliance. Which investigation is most appropriate to identify the mechanism of resistance?

Explanation

## Investigating Imatinib Resistance in CML **Key Point:** Imatinib resistance in CML is most commonly due to BCR-ABL kinase domain mutations that prevent drug binding. Identifying the specific mutation is critical for selecting appropriate second-line tyrosine kinase inhibitors (TKIs). ### Mechanism of Imatinib Resistance **High-Yield:** Approximately 50–60% of imatinib-resistant CML cases harbor BCR-ABL mutations: - **Point mutations** in the kinase domain (e.g., T315I, M351T, E255K, G250E) - **Mutations confer differential resistance** to second-line TKIs (dasatinib, nilotinib, ponatinib) - **T315I mutation** is resistant to all TKIs except ponatinib ### Why BCR-ABL Mutation Analysis is the Investigation of Choice **Clinical Pearl:** Direct sequencing or digital PCR of the BCR-ABL kinase domain is the gold standard because it: - Identifies the specific mutation responsible for resistance - Guides selection of second-line TKI (e.g., dasatinib for T315I-negative, ponatinib for T315I-positive) - Has high sensitivity and specificity - Enables risk stratification and prognosis assessment ### Comparison of Investigations in Imatinib Resistance | Investigation | Purpose | Utility in Resistance Workup | |---|---|---| | BCR-ABL mutation analysis (sequencing/digital PCR) | Identify kinase domain mutations | **Gold standard** — directs second-line TKI choice | | Repeat quantitative BCR-ABL PCR | Confirm transcript persistence | Confirms resistance but does NOT identify mechanism | | Flow cytometry | Assess blast percentage & differentiation | Detects blast crisis or disease progression, not mutation | | Bone marrow biopsy | Morphology, cellularity, fibrosis | Assesses disease burden & progression, not mutation | **Mnemonic:** **MUTATE** — **M**utation analysis, **U**nderstand resistance, **T**yrosine kinase domain, **A**lternate TKI selection, **T**est by sequencing, **E**nable targeted therapy. ### Clinical Algorithm for Imatinib Resistance ```mermaid flowchart TD A[CML on imatinib with detectable BCR-ABL]:::outcome --> B{Confirm resistance}:::decision B -->|Repeat qPCR confirms high transcript| C[BCR-ABL mutation analysis]:::action C --> D{Mutation detected?}:::decision D -->|Yes: T315I| E[Switch to ponatinib]:::action D -->|Yes: Other mutations| F[Switch to dasatinib or nilotinib]:::action D -->|No mutation| G[Assess compliance, drug levels, CYP3A4 interactions]:::action B -->|Borderline/unclear| H[Flow cytometry + mutation analysis]:::action ``` ### Additional Considerations - **Compliance assessment** is essential before attributing resistance to mutations; poor adherence is a common cause. - **CYP3A4 interactions** (e.g., with certain antifungals, anticonvulsants) can reduce imatinib levels. - **Repeat qPCR** alone does not identify the mechanism and delays appropriate second-line therapy. - **Flow cytometry** is useful if blast crisis is suspected, but does not identify mutations.